Tuning In to The C-Suite

A limited pharmacy benefit manager (PBM) reform bill may be used as a "pay for" to offset the costs of extending Medicare telehealth flexibilities, shares Kelly, of Capitol Advocacy & Government Affairs.

In this month’s episode of Meet the Board, MHE’s Managing Editor Peter Wehrwein and spoke with a new member of our editorial advisory board, Marci J. Chodroff, MD, FACP, VP of Medical Affairs at Magellan Rx Management, a Prime Therapeutics company. The two discussed Chodroff's career transition from clinical practice to pharmacy benefits management, then crossed over to highlight challenges like Medicare regulations and the growth of specialty pharmacy, focusing on oncology and GLP-1 agonists. The conversation also touched on Magellan's acquisition by Prime Therapeutics and Chodroff's focus which remains on ensuring seamless healthcare access, especially for Medicare beneficiaries, and addressing emerging challenges like cell and gene therapies.

In this episode, MHE's Peter Wehrwein spoke with Patrick Cooney, president of The Federal Group, discussing Washington's focus on Pharmacy Benefit Managers (PBMs). Cooney highlighted increased federal attention on PBMs, with legislative activity indicating bipartisan interest in reform. Despite recent setbacks in negotiations over PBM-related provisions, both Democrats and Republicans aim for transparency and change. Cooney also predicts eventual PBM legislation in 2024, emphasizing the bipartisan recognition of reform necessity.

As we bring back our "Meet the Board" Series podcast series, Managed Healthcare Executive welcomes our newest Editorial Advisory Board member Greg Baker, CEO of AffirmedRx. In this conversation, Baker and Peter Wehrwein, MHE managing editor, discussed insights from Baker's career journey. Drawing from his experiences at Walgreens and Premise Health, Baker highlighted the importance of patient-centered care and process orientation. He discussed AffirmedRx's mission to bring transparency to the PBM industry through innovative approaches such as a cloud-based system and clinically-driven formulary. Expressing concerns about opaque pricing practices, he shared the need for industry reform and cautioned against the proliferation of corporate entities within PBMs.

In this second part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein spoke with Ceci Connolly and Margaret "Meg" Murray about Medicare Advantage utilization and challenges, highlighting proposed CMS payment cuts and prior authorization issues. Murray emphasized MA's growth and benefits, while Connolly introduced MA for Tomorrow proposals. They also tackled drug pricing transparency concerns, Medicaid coverage challenges, and predicted affordability as a key issue in the 2024 elections.

In this first part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein kicks off our new podcast series "DC Roundtable," with guests Margaret "Meg" Murray, CEO of the Association of Community Affiliated Plans, and member of MHE's Editorial Advisory Board, and CeCi Connolly, president and CEO of the Alliance of Community Health Plans, for a discussion on healthcare policy issues. The trio addressed the impact of Medicaid redetermination, emphasizing ongoing challenges and the need for policy flexibility. While recognizing the ACA's success in expanding access, they highlighted affordability concerns and partisan divides. The conversation also highlighted efforts to advocate for solutions prioritizing access, affordability and quality care.

In this month’s episode of Tuning In to the C-Suite, Briana Contreras, an editor of Managed Healthcare Executive, got to chatting with Sanjula Jain, Ph.D., chief research officer at Trilliant Health. 

In the conversation, Sanjula shared the concerning rise in cancer cases among those in their 30s and 40s, despite declining mortality rates. In this age range, neoplasm-related deaths are notably increasing, which could possibly be linked to pandemic-induced declines in primary care and screenings. 

Sanjula added that rising cancer care costs and increased pharmaceutical investments highlight the need for a comprehensive approach in this space.

In this month’s episode, Briana Contreras, an editor of MHE, chatted with Lynn Carroll, executive of HSBlox, about the difference between predictive and generative AI, yet how each works together in preventive healthcare. In the discussion, Carroll expressed the challenges and opportunities with generative AI in clinical documentation, pharmaceutical research, and medical device manufacturing. Also shared were strategies for aligning primary and specialty care in value-based initiatives, along with emerging use cases, best practices for Generative AI and much more.

Briana Contreras, an editor of Managed Healthcare Executive, spoke with Fred Turner, CEO of Curative, in this month’s episode. The two talked about the challenges middle-class Americans face in dealing with medical debt, exploring the causes behind it and the impact on overall health. Fred also touched on potential solutions, both from the perspective of organizations like Curative and through collaborative efforts between various stakeholders in the healthcare system. The solutions mentioned in the conversation focus on making healthcare more financially accessible and creating a sustainable and inclusive healthcare system for all Americans.

Briana Contreras, an editor with Managed Healthcare Executive, spoke with Harsha Rajasimha, MD, founder and executive chairman of IndoUSrare, in this month's episode of Tuning in to the C-Suite podcast. The conversation was about how the disparity in diversity and ethnicity in rare disease clinical trials in the U.S. has led to gaps in understanding diseases and conditions, jeopardizing universal health, and increasing the economic burden of healthcare. Dr. Rajasimha also shared some examples of rare diseases that have been affected most by the lack of diversity in clinical trials, but even some strategies or initiatives that are being implemented to address the diversity gap in rare disease clinical trials.